Article

Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Nanomedicine (Impact Factor: 5.82). 10/2012; DOI: 10.2217/nnm.12.134
Source: PubMed

ABSTRACT Aim: Two unexplored aspects for irinotecan and cisplatin (I&C) combination chemotherapy are: actively targeting both drugs to a specific diseased cell type, and delivering both drugs on the same vehicle to ensure their synchronized entry into the cell at a well-defined ratio. In this work, the authors report the use of targeted polymeric nanoparticles (NPs) to coencapsulate and deliver I&C to cancer cells expressing the prostate-specific membrane antigen. Materials & method: Targeted NPs were prepared in a single step by mixing four different precursors inside microfluidic devices. Results: I&C were encapsulated in 55-nm NPs and showed an eightfold increase in internalization by prostate-specific membrane antigen-expressing LNCaP cells compared with nontargeted NPs. NPs coencapsulating both drugs exhibited strong synergism in LNCaP cells with a combination index of 0.2. Conclusion: The strategy of coencapsulating both I&C in a single NP targeted to a specific cell type could potentially be used to treat different types of cancer. Original submitted 24 February 2012; Revised submitted 21 June 2012.

0 Followers
 · 
203 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The simultaneous delivery of multiple cancer drugs in combination therapies to achieve optimal therapeutic effects in patients can be challenging. This study investigated whether co-encapsulation of the BH3-mimetic ABT-737 and the topoisomerase I inhibitor camptothecin (CPT) in PEGylated polymeric nanoparticles (NPs) was a viable strategy for overcoming their clinical limitations and to deliver both compounds at optimal ratios. We found that thrombocytopenia induced by exposure to ABT-737 was diminished through its encapsulation in NPs. Similarly, CPT-associated leukopenia and gastrointestinal toxicity were reduced compared with the administration of free CPT. In addition to the reduction of dose-limiting side effects, the co-encapsulation of both anticancer compounds in a single NP produced synergistic induction of apoptosis in both in vitro and in vivo colorectal cancer models. This strategy may widen the therapeutic window of these and other drugs and may enhance the clinical efficacy of synergistic drug combinations.
    Cell Death & Disease 10/2014; 5:e1454. DOI:10.1038/cddis.2014.413 · 5.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intelligent nanomaterials that are able to respond to environmental stimuli for sequential release of multiple payloads are highly desirable in applications of drug delivery systems. In this study, a core/shell-structured nanocarrier with an acid-dissolvable magnetic supraparticle (MSP) as core and a redox-degradable poly(methylacrylic acid-co-N,N-bis(acryloyl)cystamine) (P(MAA-Cy)) as shell was prepared using the distillation-precipitation polymerization technique, in which the magnetic core and the polymer shell were loaded with different guest molecules. Under physiological conditions similar to the cytoplasm of tumour cells, this MSP@P(MAA-Cy) microsphere showed a sequential degradation profile of the shell and the core. With dyes of fluorescein isothiocyanate (FITC) loaded in the core and rhodamine in the shell, the produced MSP-FITC@P(MAA-Cy)-Rho microspheres were applied in HeLa cell and HEK 293T cell cultures, showing selective degradation of the microspheres in HeLa cells to release the rhodamine and FITC dyes in sequence. When two anticancer drugs, i.e., paclitaxel (TXL) and doxorubicin (DOX), were loaded separately into the core and the shell domains of the microspheres, the experimental results showed that the MSP-TXL@P(MAA-Cy)-DOX nanodrug exhibited better inhibitive efficacy than the free drugs under the same dosing level, demonstrating the great potential of this stimuli-sensitive drug delivery system for programmed and stimuli-responsive drug release characteristics.
    07/2014; 2(32). DOI:10.1039/C4TB00756E
  • [Show abstract] [Hide abstract]
    ABSTRACT: The adjustable microfluidic droplet generator (ADG) described herein successfully uses a micro-mixer and a flow-focusing device to produce water droplets with eleven different trypan blue concentrations under various flow rate ratios of the trypan blue solution (sample phase 1, w1) and D.I. water (sample phase 2, w2) and uses these chitosan microparticles to encapsulate the magnetic nanoparticles. These eleven trypan blue/water droplet variations are uniform in size, with a coefficient of variation less than 10%, and can be precisely controlled by adjusting the sum of the sample phase flow rates (w1+w2) and the oil phase flow rate. Chitosan emulsions with eleven different Fe3O4 nanoparticle concentrations are used for magnetic targets, with the chitosan microparticles ranging from 44 to 83 ┬Ám in diameter. The ADG has the advantages of active droplet diameter control, the generation of droplets of uniform and specific size with different concentrations and the simplicity of the process. This preparation approach for chitosan microparticles with eleven different concentrations has many potential applications in drug delivery and pharmaceuticals.
    Journal of Micromechanics and Microengineering 12/2013; 23(12):5025-. DOI:10.1088/0960-1317/23/12/125025 · 1.73 Impact Factor